rxstat › Shortages › Hepatitis B Surface Antigen
Hepatitis B Surface Antigen shortage status
Partial shortage
Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Hepatitis B Surface Antigen products are in shortage in Canada (1 of 8 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Aug 10, 2026.
In shortage since
May 20, 2026
Est. full return
Aug 10, 2026
Talk to your pharmacist. Pharmacists can often substitute another manufacturer's version, a different strength, or (in most provinces) adapt or renew a prescription on the spot. Your free provincial health line is 811.
Reports by product
Active shortageRECOMBIVAX HB
10MCG · SOLUTION · MERCK CANADA INC
DIN 02561484 · since May 20, 2026, est. end Aug 10, 2026 · Demand increase for the drug.
To be discontinuedRECOMBIVAX HB
10MCG · SUSPENSION
SOLUTION · MERCK CANADA INC
DIN 02243676
ResolvedRECOMBIVAX HB
5MCG · SOLUTION · MERCK CANADA INC
DIN 02561476 · ended May 28, 2026 · Demand increase for the drug.
DiscontinuedRECOMBIVAX HB
10MCG · SUSPENSION
SOLUTION · MERCK CANADA INC
DIN 02243676
ResolvedRECOMBIVAX HB
10MCG · SUSPENSION
SOLUTION · MERCK CANADA INC
DIN 02243676 · ended Apr 23, 2026 · Other (Please describe in comments)
ResolvedRECOMBIVAX HB
10MCG · SUSPENSION
SOLUTION · MERCK CANADA INC
DIN 02243676 · ended Mar 2, 2026 · Demand increase for the drug.
DiscontinuedRECOMBIVAX HB
10MCG · SUSPENSION
SOLUTION · MERCK CANADA INC
DIN 02243676
ResolvedENGERIX-B
10MCG · SUSPENSION · GLAXOSMITHKLINE INC
DIN 02487020 · ended Apr 14, 2026 · Demand increase for the drug.
ResolvedENGERIX-B
20MCG · SUSPENSION · GLAXOSMITHKLINE INC
DIN 02487039 · ended Nov 13, 2025 · Disruption of the manufacture of the drug.
ResolvedENGERIX-B
10MCG · SUSPENSION · GLAXOSMITHKLINE INC
DIN 02487020 · ended Oct 10, 2025 · Disruption of the manufacture of the drug.
ResolvedENGERIX-B
10MCG · SUSPENSION · GLAXOSMITHKLINE INC
DIN 02487020 · ended Oct 24, 2024 · Demand increase for the drug.
ResolvedENGERIX-B
10MCG · SUSPENSION · GLAXOSMITHKLINE INC
DIN 02487020 · ended Sep 4, 2024 · Delay in shipping of the drug.
Showing 12 of 32 reports. All reports are on file with Health Canada.
What's happening
Hepatitis B Surface Antigen is currently affected by an active shortage report filed with Health Canada by MERCK CANADA INC.
The reported cause is: demand increase for the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Hepatitis B Surface Antigen is classified under “VIRAL VACCINES” (ATC J07BC).
Recent changes
Common questions
When will Hepatitis B Surface Antigen be back in stock in Canada?
The latest manufacturer estimate is Aug 10, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Hepatitis B Surface Antigen in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Guides: what to do when your medication is in shortage · how to read shortage reports
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.